Cytokinetics (CYTK) Competitors $46.16 +4.54 (+10.91%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$46.25 +0.09 (+0.19%) As of 02/14/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CYTK vs. TEVA, BGNE, SMMT, ITCI, VTRS, GMAB, MRNA, RDY, SRPT, and PCVXShould you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Viatris (VTRS), Genmab A/S (GMAB), Moderna (MRNA), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry. Cytokinetics vs. Teva Pharmaceutical Industries BeiGene Summit Therapeutics Intra-Cellular Therapies Viatris Genmab A/S Moderna Dr. Reddy's Laboratories Sarepta Therapeutics Vaxcyte Teva Pharmaceutical Industries (NYSE:TEVA) and Cytokinetics (NASDAQ:CYTK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, community ranking, valuation, analyst recommendations, earnings, media sentiment, profitability, institutional ownership and dividends. Do insiders & institutionals believe in TEVA or CYTK? 54.1% of Teva Pharmaceutical Industries shares are held by institutional investors. 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Comparatively, 3.4% of Cytokinetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts prefer TEVA or CYTK? Teva Pharmaceutical Industries currently has a consensus price target of $23.57, indicating a potential upside of 45.19%. Cytokinetics has a consensus price target of $82.00, indicating a potential upside of 77.64%. Given Cytokinetics' stronger consensus rating and higher probable upside, analysts clearly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Teva Pharmaceutical Industries 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Cytokinetics 0 Sell rating(s) 2 Hold rating(s) 15 Buy rating(s) 1 Strong Buy rating(s) 2.94 Does the MarketBeat Community favor TEVA or CYTK? Teva Pharmaceutical Industries received 515 more outperform votes than Cytokinetics when rated by MarketBeat users. However, 79.92% of users gave Cytokinetics an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote. CompanyUnderperformOutperformTeva Pharmaceutical IndustriesOutperform Votes133167.87% Underperform Votes63032.13% CytokineticsOutperform Votes81679.92% Underperform Votes20520.08% Which has more risk & volatility, TEVA or CYTK? Teva Pharmaceutical Industries has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Cytokinetics has a beta of 0.83, meaning that its stock price is 17% less volatile than the S&P 500. Is TEVA or CYTK more profitable? Teva Pharmaceutical Industries has a net margin of -9.91% compared to Cytokinetics' net margin of -17,906.25%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Cytokinetics' return on equity.Company Net Margins Return on Equity Return on Assets Teva Pharmaceutical Industries-9.91% 42.46% 6.65% Cytokinetics -17,906.25%N/A -50.21% Does the media prefer TEVA or CYTK? In the previous week, Cytokinetics had 7 more articles in the media than Teva Pharmaceutical Industries. MarketBeat recorded 21 mentions for Cytokinetics and 14 mentions for Teva Pharmaceutical Industries. Teva Pharmaceutical Industries' average media sentiment score of 0.79 beat Cytokinetics' score of 0.09 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Teva Pharmaceutical Industries 9 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Cytokinetics 2 Very Positive mention(s) 0 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral Which has higher valuation & earnings, TEVA or CYTK? Cytokinetics has lower revenue, but higher earnings than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTeva Pharmaceutical Industries$16.54B1.11-$1.64B-$1.45-11.20Cytokinetics$3.22M1,692.30-$526.24M-$5.38-8.58 SummaryCytokinetics beats Teva Pharmaceutical Industries on 11 of the 19 factors compared between the two stocks. Get Cytokinetics News Delivered to You Automatically Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYTK vs. The Competition Export to ExcelMetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.45B$6.84B$5.76B$9.22BDividend YieldN/A2.90%5.27%3.99%P/E Ratio-8.589.6826.1919.41Price / Sales1,692.30317.72464.8976.77Price / CashN/A75.4646.1438.90Price / Book-11.725.537.285.05Net Income-$526.24M$123.46M$3.19B$222.81M7 Day Performance9.36%1.37%1.68%1.29%1 Month Performance0.92%2.09%4.10%1.52%1 Year Performance-39.97%1.28%22.06%16.53% Cytokinetics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYTKCytokinetics4.4052 of 5 stars$46.16+10.9%$82.00+77.6%-40.0%$5.45B$3.22M-8.58250High Trading VolumeTEVATeva Pharmaceutical Industries3.0166 of 5 stars$16.82-0.1%$23.57+40.2%+24.7%$19.05B$16.54B-11.6037,851Short Interest ↑BGNEBeiGene1.759 of 5 starsN/A$253.69+∞N/A$18.03B$3.32B-22.429,000SMMTSummit Therapeutics2.6207 of 5 stars$20.50+1.9%$33.57+63.8%+321.5%$15.12B$700,000.00-73.21110ITCIIntra-Cellular Therapies4.0172 of 5 stars$127.12+0.1%$103.62-18.5%+69.0%$13.52B$612.78M-146.11560Analyst ForecastShort Interest ↑VTRSViatris3.3601 of 5 stars$10.62-1.0%$13.67+28.7%-17.3%$12.68B$15.43B-14.3538,000GMABGenmab A/S4.7976 of 5 stars$18.69-1.6%$45.20+141.8%-25.8%$12.37B$2.39B18.152,204Earnings ReportShort Interest ↓Analyst RevisionMRNAModerna4.8388 of 5 stars$31.87-2.2%$67.26+111.1%-62.7%$12.26B$6.85B-5.485,600Gap DownRDYDr. Reddy's Laboratories2.9941 of 5 stars$13.83-0.5%$17.00+23.0%-10.0%$11.54B$3.35B22.0127,048Short Interest ↑Analyst RevisionGap DownSRPTSarepta Therapeutics4.5304 of 5 stars$112.74+0.8%$178.71+58.5%-19.8%$10.77B$1.24B90.191,314PCVXVaxcyte2.7194 of 5 stars$85.94-1.7%$145.71+69.6%+11.6%$10.71BN/A-18.68160Positive News Related Companies and Tools Related Companies Teva Pharmaceutical Industries Alternatives BeiGene Alternatives Summit Therapeutics Alternatives Intra-Cellular Therapies Alternatives Viatris Alternatives Genmab A/S Alternatives Moderna Alternatives Dr. Reddy's Laboratories Alternatives Sarepta Therapeutics Alternatives Vaxcyte Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CYTK) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Cytokinetics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.